Two technology stories spotlight efforts to scale single‑cell and variant‑effect assays for translational discovery. Swedish spinout Epigenovo is commercializing scFFPE‑ATAC, a single‑cell chromatin accessibility assay compatible with FFPE clinical samples; the company published proof‑of‑concept in Nature Communications and is raising funding to kit the workflow for clinical labs. FFPE compatibility is central to translating epigenetic measurements into real‑world clinical samples. Separately, Parse Biosciences and Codebreaker Labs formed a collaboration to test how engineered genetic variants affect single‑cell transcriptomes, combining engineered variant libraries with Parse’s high‑throughput single‑cell platform. The effort aims to generate experimental datasets to interpret variants, validate targets and inform AI models used for target discovery and trial design. Together these developments accelerate the experimental throughput needed for target validation and precision medicine.